A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma

202231 citationsJournal Articlebronze Open Access

Authors

Giselle L. Saulnier Sholler · Levine Children's Hospital

Dan G. Duda · Massachusetts General Hospital

Genevieve Bergendahl · Levine Children's Hospital

David H. Ebb · Massachusetts General Hospital

Matija Snuderl · NYU Langone Health

Theodore W. Laetsch · Children's Hospital of Philadelphia

Jennifer Michlitsch

Abstract

TB-403 was safe and well tolerated at all dose levels. No MTD was reached. The results look encouraging and therefore warrant further evaluation of efficacy in pediatric subjects with medulloblastoma.

Topics & Keywords

Angiogenesis and VEGF in Cancer Glioma Diagnosis and Treatment Neuroblastoma Research and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 28, Issue 18, pp. 3950-3957

DOI: 10.1158/1078-0432.ccr-22-1169

Field-Weighted Citation Impact: 2.60